SynapDx Licenses Gene Expression Technology from Children's Hospital Boston | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Startup SynapDx said today it has licensed technology from Children's Hospital Boston for the development of blood-based tests for the early detection of autism spectrum disorders.

Citing statistics from the Centers for Disease Control, SynapDx said about one in every 110 children in the US has the disorder.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.